Yeshwant V. Kurhe
Pilani, RJ, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 28, 2023
Knockout of STE20-type kinase TAOK3 does not attenuate diet-induced NAFLD development in mice.
Journal: Molecular medicine (Cambridge, Mass.)
Published: August 02, 2023
Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
Journal: Cellular and molecular gastroenterology and hepatology
Published: April 22, 2021
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models.
Journal: Nature communications
Published: February 27, 2021
STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes.
Journal: Hepatology communications
Published: November 11, 2020
Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver.
Journal: Journal of lipid research
Published: August 06, 2019
Ondansetron ameliorates depression associated with obesity in high-fat diet fed experimental mice: An investigation-based on the behavioral, biochemical, and molecular approach.
Journal: Indian journal of pharmacology
Published: January 13, 2018
Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice.
Journal: Psychopharmacology
Published: July 20, 2016
Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice.
Journal: Neurobiology of stress
Published: September 23, 2015
Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention.
Journal: Asian journal of psychiatry
Published: April 21, 2015
Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
Journal: Pharmacology, biochemistry, and behavior
Published: March 26, 2015
A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation.
Journal: Pharmaceutical biology
Published: November 29, 2014
Last Updated: 09/26/2026